DURECT

DURECT Corp. focuses on advancing novel and potentially lifesaving investigational therapies derived from its Epigenetic Regulator Program. Its pipeline is called DUR-928, an endogenous sulfated oxysterol and an epigenetic regulator. The company was founded by James E. Brown and Felix Theeuwes on February 6, 1998 and is headquartered in Cupertino, CA.

Earnings data Q1 2024

DURECT Corporation reports Q1 earnings, highlights larsucosterol's potential in AH

DRRX's earnings call highlighted the progress of larsucosterol in alcohol-associated hepatitis, addressing potential challenges and emphasizing opportunities for market penetration and awareness. The company's financials and strategic initiatives were also discussed, providing insights into their performance and future prospects.

DURECT Corporation maintains stable Q2 performance, eyes oncology expansion

DURECT Corporation's Q2 2023 performance remained stable, with ongoing progress in clinical trials and expansion into oncology. However, challenges related to program screening and resource allocation require careful management. The upcoming AHFIRM trial data and future oncology trials offer potential for growth.

DRRX reports Q3 revenue decline, larsucosterol shows promising AH results

DRRX reported a decrease in revenues but showcased promising results from the AHFIRM trial for larsucosterol in AH. The drug's potential in addressing AH and its positive reception from the medical community position it as a significant opportunity. However, challenges related to trial endpoints and regulatory engagement need to be navigated effectively.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Durect (DRRX) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.46 per share a year ago.

Durect (DRRX) Reports Q4 Loss, Misses Revenue Estimates

DURECT Corporation (DRRX) Q4 2023 Earnings Call Transcript

- Ongoing Communication with FDA to Align on Next Steps for Larsucosterol in Alcohol-Associated Hepatitis - Webcast of Earnings Call Today, March 27th at 4:30 p.m. ET CUPERTINO, Calif.

DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

CUPERTINO, Calif. , March 20, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that the company will report its fourth quarter and full year 2023 financial results on Wednesday, March 27, 2024.

DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update

Partnership agreement will be the first-ever co-marketing and sales collaboration for the ALZET Osmotic Pumps Portfolio and Associated Product Line in the U.S. and Canada Both companies will jointly market and commercialize the ALZET product line to customers over a multi-year period CUPERTINO, Calif. , March 4, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), today announced that it has entered into a co-marketing and collaboration agreement with Charles River Laboratories for the ALZET® Osmotic Pumps Portfolio and Associated Product Line in the U.S. and Canada.

DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada

CUPERTINO, Calif. , Feb. 7, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that James E.

DURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Aadi Bioscience

Kintara Therapeutics

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 3 Health Care Stocks That Are Preparing To Pump This Month - Durect (NASDAQ:DRRX), Aadi Bioscience (NASDAQ:AADI)

DURECT Corporation (NASDAQ:DRRX ) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Tim Papp - Chief Financial Officer Jim Brown - Chief Executive Officer Conference Call Participants François Brisebois - Oppenheimer Carl Byrnes - Northland Capital Markets Thomas Yip - H.C. Wainwright Operator Good afternoon, everyone, and welcome to the DURECT Corporation Third Quarter Earnings Conference Call.

DURECT Corporation (DRRX) Q3 2023 Earnings Call Transcript

-  Webcast of Earnings Call Today, November 13th at 4:30 p.m. ET -  Topline data from AHFIRM trial showed compelling efficacy signal in favor of larsucosterol in the key secondary endpoint of mortality at 90 days CUPERTINO, Calif.

DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update

CUPERTINO, Calif. , Nov. 9, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that the company will report its financial results for the three months ended September 30, 2023 on Monday, November 13, 2023.

DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business Update

Durect (NASDAQ: DRRX ) stock is falling hard on Wednesday after the late-stage biopharmaceutical company released results from a Phase 2b clinical trial. This clinical trial covered the efficiency of larsucosterol in treating patients with severe alcohol-associated hepatitis.

Why Is Durect (DRRX) Stock Down 64% Today?

Compelling efficacy signal in favor of larsucosterol in the key secondary endpoint of mortality at 90 days.  Clinically relevant reduction in 90-day mortality of 41% for 30 mg dose and 35% for 90 mg dose compared with standard of care (SOC) Numerical improvement in primary endpoint of mortality or transplant at 90 days did not achieve statistical significance More pronounced effect in the U.S. trial population of 232 patients, representing 76% of the trial population, with a clinically meaningful 90-day mortality reduction of 57% for 30 mg dose and 58% for 90 mg dose compared with SOC Larsucosterol was well-tolerated and both 30 mg and 90 mg dose groups had numerically fewer adverse events than SOC Strong rationale for advancing larsucosterol in a Phase 3 registration trial in alcohol-associated hepatitis with reduction in 90-day mortality as the primary endpoint DURECT will host a conference call and webcast at 5 p.m.

DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality

eFFECTOR Therapeutics Inc

Nkarta, Inc.

For investment ideas that can potentially lead to life-changing gains, few sectors are as viable as biotech stocks to make you rich. Fundamentally, the biotechnology sector offers potential therapeutic innovations that could change paradigms for patient care.

3 Promising Biotech Stocks That Will Make Early Investors Rich

Company on track to report topline data from AHFIRM in Q4 2023 CUPERTINO, Calif. , Sept. 7, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that the last patient has completed the study protocol in the Company's AHFIRM trial.

DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis

CUPERTINO, Calif. , Aug. 31, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program , will present in the following September 2023 conferences.

DURECT Corporation Announces Presentations in Upcoming Investor Conferences

DURECT Corporation (NASDAQ:DRRX ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Timothy Papp - CFO & Secretary James Brown - Co-Founder, CEO, President & Director WeiQi Lin - EVP, Research & Development and Principal Scientist Keith Lui - SVP, Business Development, Commercial & Medical Affairs Conference Call Participants Richard Miller - Cantor Fitzgerald Francois Brisebois - Oppenheimer Antonio Arce - H.C. Wainwright & Co. Sean Kim - JonesTrading Operator Greetings, and welcome to the DURECT Corporation Second Quarter Earnings Call.

DURECT Corporation (DRRX) Q2 2023 Earnings Call Transcript

Durect (DRRX) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.50 per share a year ago.

Durect (DRRX) Reports Q2 Loss, Misses Revenue Estimates

-    Webcast of Earnings Call Today, August 9th at 4:30 p.m. ET -    Topline data from AHFIRM trial expected in Q4 2023 CUPERTINO, Calif.

DURECT Corporation Reports Second Quarter 2023 Financial Results and Business Update

CUPERTINO, Calif. , Aug. 3, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program, today announced that the company will report its financial results for the three months ended June 30, 2023 on Wednesday, August 9, 2023.

DURECT Corporation to Announce Second Quarter 2023 Financial Results and Provide a Business Update

CUPERTINO, Calif. , July 20, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) ("DURECT"), a biopharmaceutical company focused on developing its epigenetic regulator program for the treatment of acute organ injury and chronic liver diseases, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 2,991,027 shares of common stock and accompanying warrants to purchase up to 2,991,027 shares of common stock in a registered direct offering (the "Offering") priced at-the-market under Nasdaq rules.

DURECT Corporation Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Topline data anticipated in Q4 2023 CUPERTINO, Calif. , June 7, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company developing epigenetic therapies for the treatment of acute organ injuries and chronic liver diseases, today announced that it has completed enrollment in its Phase 2b AHFIRM clinical trial (NCT04563026) investigating larsucosterol for the treatment of patients with severe alcohol-associated hepatitis (AH), achieving its enrollment target of 300 patients.

DURECT Completes Enrollment in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis

The mean of analysts' price targets for Durect (DRRX) points to a 595% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think Durect (DRRX) Could Surge 594.98%: Read This Before Placing a Bet

DURECT Corporation (NASDAQ:DRRX ) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ET Company Participants Tim Papp - Chief Financial Officer Jim Brown - Chief Executive Officer Keith Lui - Senior Vice President, Business Development, Commercial, Medical Affairs WeiQi Lin - Executive Vice President, Research and Development, Principal Scientist Norman Sussman - Chief Medical Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Ed Arce - H.C. Wainwright Francois Brisebois - Oppenheimer Sean Kim - Jones Trading Operator Greetings and welcome to the DURECT Corporation First Quarter 2023 Earnings Call.

DURECT Corporation (DRRX) Q1 2023 Earnings Call Transcript

Durect (DRRX) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.50 per share a year ago.

Durect (DRRX) Reports Q1 Loss, Misses Revenue Estimates

- Webcast of Earnings Call Today, May 8th at 4:30 p.m. ET - Topline data from AHFIRM trial expected in 2H 2023 CUPERTINO, Calif.

News for DURECT Stock (DRRX)